- Home
- SGRY vs VKTX Comparison
SGRY vs VKTX Comparison
Compare SGRY & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRY
- VKTX
- Stock Information
- Founded
- SGRY 2004
- VKTX 2012
- Country
- SGRY United States
- VKTX United States
- Employees
- SGRY N/A
- VKTX N/A
- Industry
- SGRY Hospital/Nursing Management
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGRY Health Care
- VKTX Health Care
- Exchange
- SGRY Nasdaq
- VKTX Nasdaq
- Market Cap
- SGRY 2.8B
- VKTX 2.8B
- IPO Year
- SGRY 2015
- VKTX 2015
- Fundamental
- Price
- SGRY $22.73
- VKTX $28.17
- Analyst Decision
- SGRY Buy
- VKTX Buy
- Analyst Count
- SGRY 8
- VKTX 12
- Target Price
- SGRY $35.43
- VKTX $84.00
- AVG Volume (30 Days)
- SGRY 890.8K
- VKTX 4.4M
- Earning Date
- SGRY 05-12-2025
- VKTX 04-23-2025
- Dividend Yield
- SGRY N/A
- VKTX N/A
- EPS Growth
- SGRY N/A
- VKTX N/A
- EPS
- SGRY N/A
- VKTX N/A
- Revenue
- SGRY $3,114,300,000.00
- VKTX N/A
- Revenue This Year
- SGRY $10.88
- VKTX N/A
- Revenue Next Year
- SGRY $9.21
- VKTX N/A
- P/E Ratio
- SGRY N/A
- VKTX N/A
- Revenue Growth
- SGRY 13.52
- VKTX N/A
- 52 Week Low
- SGRY $19.50
- VKTX $18.92
- 52 Week High
- SGRY $33.97
- VKTX $81.81
- Technical
- Relative Strength Index (RSI)
- SGRY 53.41
- VKTX 56.08
- Support Level
- SGRY $21.30
- VKTX $26.37
- Resistance Level
- SGRY $23.29
- VKTX $30.28
- Average True Range (ATR)
- SGRY 0.54
- VKTX 1.62
- MACD
- SGRY 0.22
- VKTX 0.31
- Stochastic Oscillator
- SGRY 73.76
- VKTX 66.40
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.